Allogenic pluripotent stem cell therapy (Life Science Institute)

N/A

Report date: 2023/01/12 15:30:16

Base Information

Drug NameAllogenic pluripotent stem cell therapy (Life Science Institute)

Drug Alias NameMesenchymal stem cell therapy (Life Science Institute)Muse cell-based product (iv, ischemic stroke)Pluripotent stem Technologies cell therapy (Life Science Institute)Allogenic stem cell therapy (Life Science Institute)CL-2020

ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy

Mechanisms of ActionStem cell replacements

TargetsNot applicable

Therapy Area/IndicationsHypoxia-Ischemia, Brain

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryJapan

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesMitsubishi Chemical

China Registration ClassN/A

Develop Information

Active CompaniesNagoya University

Inactive CompaniesN/A

Active IndicationsHypoxia-Ischemia, Brain

Inactive IndicationsN/A

Other Information

ATC CodeN/A